Associated Papers
Clinical Application of Pharmacogenomics in Stroke Management: Current Evidence and Future Directions.
Lee KJ et al.
Journal of Stroke, 2026
The association of Cytochrome 4F2 rs2108622 genetic variant and non-genetic factors with essential hypertension among Jordanian patients attending the University of Jordan Hospital.
Alkasasbeh EY et al.
Prostaglandins & Other Lipid Mediators, 2025
Genome-wide screening of pharmacogenomic biomarkers in jordanian patients with genetic disorders.
Jarrar Y et al.
The Pharmacogenomics Journal, 2025
Predictor Role of VKORC1 rs9923231, CYP4F2 rs2108622, and GGCX rs11676382 Polymorphisms of 5 Years Mortality of Patients with Acute Ischemic Stroke.
Iluţ S et al.
Medicina (kaunas, Lithuania), 2025
Molecular Determinants of the Human Retinal Pigment Epithelium Cell Fate and Potential Pharmacogenomic Targets for Precision Medicine.
Zibetti C
International Journal of Molecular Sciences, 2025
Genetic Variability of CYP4F2, CYP2D6, CYP2E1, and ACE in the Chinese Yi Population.
Guo J et al.
Biochemical Genetics, 2025
Contrastive sequence signatures between the both sides of a recombination spot reveal an adaptation at PPARD locus from standing variation for pleiotropy since out-of-Africa dispersal.
Shou W et al.
Bmc Genomics, 2025
Endogamy and high prevalence of deleterious mutations in India: evidence from strong founder events.
Machha P et al.
Journal of Genetics and Genomics = Yi Chuan Xue Bao, 2025
The pharmacogenomic landscape in the Chinese: An analytics of pharmacogenetic variants in 206,640 individuals.
Wang LY et al.
Innovation (cambridge (mass.)), 2025
The impact of genetic variability on Alzheimer's therapies: obstacles for pharmacogenetic progress.
Cacabelos R et al.
Expert Opinion on Drug Metabolism & Toxicology, 2025
Exome sequencing reveals a rare damaging variant in GRIN2C in familial late-onset Alzheimer's disease.
Rubino E et al.
Alzheimer's Research & Therapy, 2025
Genome-wide association study reveals shared and distinct genetic architecture of fatty acids and oxylipins in the Hispanic Community Health Study/Study of Latinos.
Downie CG et al.
Hgg Advances, 2025
Value of Pharmacogenetic Testing Assessed with Real-World Drug Utilization and Genotype Data.
Litonius K et al.
Clinical Pharmacology and Therapeutics, 2025
Pharmacodynamic Modeling of Warfarin Dosing Algorithm for Cardiovascular Patients in Indonesia: A Tailored Method to Anticoagulation Therapy.
Putriana NA et al.
Drug Design, Development and Therapy, 2025
The impact of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin dose requirement in Saudi patients.
Jokhab S et al.
Frontiers in Pharmacology, 2025
Pharmacogenomics and genetic ancestry in Colombia: a study on all variant drug annotations of PharmGKB.
Acosta-Monterrosa AA et al.
Frontiers in Pharmacology, 2025
Application of rapid genotyping of Warfarin individualized pharmacogenetic variants in Warfarin therapy.
Huang D et al.
Scientific Reports, 2024
Phenotype driven molecular genetic test recommendation for diagnosing pediatric rare disorders.
Chen F et al.
Npj Digital Medicine, 2024
PharmVar GeneFocus: CYP4F2.
Zubiaur P et al.
Clinical Pharmacology and Therapeutics, 2024
Lipidomic biomarkers in plasma correlate with disease severity in adrenoleukodystrophy.
Jaspers YRJ et al.
Communications Medicine, 2024
Leveraging QSP Models for MIPD: A Case Study for Warfarin/INR.
Falkenhagen U et al.
Clinical Pharmacology and Therapeutics, 2024
Four-dimensional lipidomics profiling in X-linked adrenoleukodystrophy using trapped ion mobility mass spectrometry.
Jaspers YRJ et al.
Journal of Lipid Research, 2024
Precision medicine in cardiovascular therapeutics: Evaluating the role of pharmacogenetic analysis prior to drug treatment.
Ingelman-Sundberg M et al.
Journal of Internal Medicine, 2024
ACE Phenotyping in Human Blood and Tissues: Revelation of ACE Outliers and Sex Differences in ACE Sialylation.
Enyedi EE et al.
Biomedicines, 2024
Cytochrome P450 Family 4F2 and 4F11 Haplotype Mapping and Association with Hepatic Gene Expression and Vitamin K Hydroxylation Activity.
Alade AN et al.
Acs Pharmacology & Translational Science, 2024
Utility of Cytochrome P450 4F2 Genotyping to Assess Drug Interaction Risk for Brincidovovir, a Cytochrome P450 4F2 Substrate.
Tippin T et al.
Clinical Pharmacology in Drug Development, 2024
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
Pharmacogenomic Considerations for Anticoagulant Prescription in Patients with Hereditary Haemorrhagic Telangiectasia.
McCarley SC et al.
Journal of Clinical Medicine, 2023
Functional Characterization of 29 Cytochrome P450 4F2 Variants Identified in a Population of 8380 Japanese Subjects and Assessment of Arachidonic Acid ω-Hydroxylation.
Sato Y et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2023
Indicators of HSV1 Infection, ECM-Receptor Interaction, and Chromatin Modulation in a Nuclear Family with Schizophrenia.
Huang YC et al.
Journal of Personalized Medicine, 2023
Whole-genome sequencing across 449 samples spanning 47 ethnolinguistic groups provides insights into genetic diversity in Nigeria.
Joshi E et al.
Cell Genomics, 2023
Association of CYP4A22 gene polymorphisms with cerebral stroke risk in the Chinese Han population.
Zhuo Q et al.
The Journal of Gene Medicine, 2023
Frequency of polymorphisms in the CYP2C9, VKORC1, and CYP4F2 genes related to the metabolism of Warfarin in healthy donors from Cali, Colombia.
Giraldo-Ocampo S et al.
Medicine, 2023
Efficacy of Warfarin Therapy Guided by Pharmacogenetics: A Real-world Investigation Among Han Taiwanese.
Liu TY et al.
Clinical Therapeutics, 2023
Evaluation of a warfarin dosing algorithm including CYP2C9, VKORC1, and CYP4F2 polymorphisms and non-genetic determinants for the Iranian population.
Farajzadeh-Dehkordi M et al.
Pharmacological Reports : Pr, 2023
CYP4F2 is a human-specific determinant of circulating N-acyl amino acid levels.
Tanzo JT et al.
The Journal of Biological Chemistry, 2023
Genetic Factors Influencing Warfarin Dose in Han Chinese Population: A Systematic Review and Meta-Analysis of Cohort Studies.
Zhao Z et al.
Clinical Pharmacokinetics, 2023
Computational analysis of missense variant CYP4F2*3 (V433M) in association with human CYP4F2 dysfunction: a functional and structural impact.
Farajzadeh-Dehkordi M et al.
Bmc Molecular and Cell Biology, 2023
Insights into the binding mechanism between α-TOH and CYP4F2: A homology modeling, molecular docking, and molecular dynamics simulation study.
Liang L et al.
Journal of Cellular Biochemistry, 2023
CYP4F2 is a human-specific determinant of circulating N-acyl amino acid levels.
Tanzo JT et al.
Biorxiv : the Preprint Server for Biology, 2023
Pharmacogenetics of anxiety and depression in Alzheimer's disease.
Cacabelos R et al.
Pharmacogenomics, 2023
Characterization of pharmacogenomic variants in a Brazilian admixed cohort of elderly individuals based on whole-genome sequencing data.
Bertholim-Nasciben L et al.
Frontiers in Pharmacology, 2023
The pharmacogenomic landscape of an Indigenous Australian population.
Samarasinghe SR et al.
Frontiers in Pharmacology, 2023
One Rare Warfarin Resistance Case and Possible Mechanism Exploration.
Zhao L et al.
Pharmacogenomics and Personalized Medicine, 2023
Targeted haplotyping in pharmacogenomics using Oxford Nanopore Technologies' adaptive sampling.
Deserranno K et al.
Frontiers in Pharmacology, 2023